


PCI for Long Coronary Lesion

Problems of PCI for Long Coronary Lesion


- Low procedural success rate
- High complication rate
- High restenosis rate

Higher Restenosis Rate With Long Lesion and Multiple Stents



Kastrati A, AJC 1999;83:1617-22


Worse Clinical Outcome With Increasing Lesion Length



Kastrati A, AJC 1999;83:1617-22


Higher Restenosis Rate With Increasing Stent Length

(The Multi-link Stent Trials)



Kereiakes D, et al. AJC 2000;86:336-341

Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area




De Feyter. Circulation 1999; 100:1777-83

*Full Lesion Coverage
Vs.
Spot Stenting*

Event Free Survival

MAGIC 5L




Foley DP et al, Eur Heart J 2001;22:1585-93

Restenosis Rate

MAGIC 5L

$$\text{Restenosis Rate} = 32.1 + 0.435 \times \text{stent length}$$




Foley DP et al, Eur Heart J 2001;22:1585-93

Probability of MACE

ADVANCE

Stent is better than balloon PTCA in lesions with length ≤ 30 mm




Serruys PW et al, J Am Coll Cardiol 2002;39:393-9

Restenosis Rate

ADVANCE

Stent is better than balloon PTCA in lesions with length ≤ 32 mm



Serruys PW et al, J Am Coll Cardiol 2002;39:393-9

Acceptable Stent Length Expected for Better Outcome than Balloon PTCA

ADVANCE Trial

Stent Length \leq 32 mm

Expected TVR = 13 %

Strategy of Spot Stenting

**Stenting in lesions with
CSA $\leq 5.5 \text{ mm}^2$ or
Diameter Stenosis $\geq 50\%$
After Balloon PTCA
In Long Lesion PCI**

Colombo A et al, J Am Coll Cardiol 2001;38:1427-33

Spot Stenting vs. Long Stent

	Short stent (n=101)	Long stent (n=121)	P value
Lesion length, mm	29.3	27.3	NS
Stent length, mm	21	42.6	<0.001
No. of stent	1.2	2.3	<0.05
Stent Thrombosis (%)	0.8	2.1	NS
Restenosis Rate (%)	25	39	<0.05
TLR (%)	19	34	<0.05
6 month MACE (%)	22	38	<0.05
Small Ref.vessel			
Restenosis Rate (%)	29	52	<0.05
TLR (%)	21	34	NS

Colombo A et al, J Am Coll Cardiol 2001;38:1427-33


Spot Stenting vs. Long Stent

6 Months MACE

Restenosis Rate

■ Spot stenting

■ Long stenting



Colombo A et al, J Am Coll Cardiol 2001;38:1427-33

*Single Long Stent
Vs.
Multiple Stents*

IMPULSE Trial


Lesion length : 20 to 40 mm

- Two stents with GFX II or S670 (n=62)
- One long stent with GFX II or S670 (n=62)

Hoffmann R, et al. Am J Cardiol 2002;90:460-464

Restenosis Rate

IMPULSE





Hoffmann R, et al. Am J Cardiol 2002;90:460-464

Cost-Effectiveness

IMPULSE

Contrast agent

Intervention Cost



Hoffmann R, et al. Am J Cardiol 2002;90:460-464

Stenting with Bare Metal Stent for Long Coronary Lesion

We suggest ...


- Spot stenting
- Single stent

*Does the strategy
need to be changed ?*

In the Era of
Drug Eluting Stent

No Abrupt Increase of Restenosis with Stent length of DES

SIRIUS : Sirolimus Eluting Stent



TCT, Oct 2002

Relative Reduction of Restenosis

SIRIUS : Sirolimus Eluting Stent

Non-diabetic

Lesion length


	< 12mm	12 – 15 mm	≥ 15mm
Ref Dia > 3.0mm	81.7 %	81.2 %	80.4 %
2.5 – 3.0 mm	79.8 %	79.2 %	77.9 %
< 2.5mm	77.6 %	76.6 %	74.8 %

Diabetic

	< 12mm	12 – 15 mm	≥ 15mm
Ref Dia > 3.0mm	78.0 %	77.0 %	75.3 %
2.5 – 3.0 mm	74.1 %	72.7 %	70.2 %
< 2.5mm	69.6 %	67.8 %	64.5 %

Restenosis in Lesions ≥ 10 mm in stented segment

TAXUS II : Paclitaxel Eluting Stent



Grube E, ACC, 2003

Impact of Stent Overlapping


SIRIUS : Sirolimus Eluting Stent

	Sirolimus (n=176)	Control (n=168)	P value
Late loss (mm)			
In-stent	0.23	1.14	<0.001
In-segment	0.20	0.93	<0.001
Restenosis (%)			
In-stent	7.1	42.7	<0.001
In-segment	8.8	42.7	<0.001

TCT, Oct 2002

Restenosis in > 1 Stent in stented segment

TAXUS II : Paclitaxel Eluting Stent



Grube E, ACC, 2003

Strategy in PCI with DES

It should be changed to be ...

- Full lesion coverage
- No scary of stent overlapping